Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema dose-comparison study in adults with obesity with or without type 2 diabetes
PACTR202607641626021Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of CagriSema and semaglutide in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
CagriSemasemaglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202607641626021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607641626021.